TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02590367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HD6610 Granule placebo
Description: the HD6610 Granule placebo will be given 2 times a day.
Study: NCT03978338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: brain polypeptide solution
Description: The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: same package of placebo
Description: The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
Study: NCT00900965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))
Description: A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))
Description: Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
Study: NCT00404261

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone/Salmeterol HFA
Description: Fluticasone/Salmeterol HFA, 2 puffs twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone/Salmeterol HFA
Description: Fluticasone/Salmeterol HFA, 2 puffs twice daily
Study: NCT03522935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafin
Description: Elafin subcutaneous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafin
Description: Elafin subcutaneous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafin
Description: Elafin subcutaneous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafin
Description: Elafin subcutaneous.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous.
Study: NCT02704975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation and Dry Needling
Description: Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
Study: NCT01541007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: 25 mg/m2 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly cabazitaxel
Description: 10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
Study: NCT01018173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
Study: NCT03780621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrographis and Withania
Description: Combination of Andrographis paniculata and Withania somnifera

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo capsule
Study: NCT02154334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
Study: NCT04071561

Intervention type: OTHER
Intervention: Posterior retroperitoneal adrenalectomy (PRA)
Description: Minimally invasive adrenalectomy procedure

Intervention type: OTHER
Intervention: Posterior retroperitoneal adrenalectomy (PRA)
Description: Minimally invasive adrenalectomy procedure

Intervention type: OTHER
Intervention: Lateral transperitoneal adrenalectomy (LTA)
Description: During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
Study: NCT04286243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based HPV screening strategy
Description: Offering HPV self-collection for cervical cancer screening in the community
Study: NCT04944238

Intervention type: DEVICE
Intervention: Ankoris
Description: Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
Study: NCT04188834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized version of DAVID device
Description: A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blackrock CereStim
Description: The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
Study: NCT00770627

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 caps
Description: Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 caps
Description: Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
Study: NCT03755219

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study: NCT04286243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based HPV screening strategy
Description: Offering HPV self-collection for cervical cancer screening in the clinic
Study: NCT02429544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential Program
Description: Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential Program
Description: Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
Study: NCT03755219

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study: NCT02429544

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalogram (EEG)
Description: EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva Testing
Description: Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Diary plus Actigraph
Description: For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Diary plus Actigraph
Description: For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study Diary plus Actigraph
Description: For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
Study: NCT04101461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: PharaFerro27; Devart Lab Company, Egypt

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: PharaFerro27; Devart Lab Company, Egypt

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Complete blood count
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Complete blood count
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum ferritin
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum ferritin
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum hepcidin
Description: to assess the iron abosrption
Study: NCT03755219

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study: NCT04101461

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum hepcidin
Description: to assess the iron abosrption

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Iron
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Iron
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum total iron binding capacity
Description: to assess the anemia

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum total iron binding capacity
Description: to assess the anemia
Study: NCT03755219

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device

Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study: NCT00694577

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 32 Gy / 8 fractions
Description: 32 Gy-8 Treatments, 4 Treatment Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 32 Gy / 8 fractions
Description: 32 Gy-8 Treatments, 4 Treatment Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 32 Gy / 8 fractions
Description: 32 Gy-8 Treatments, 4 Treatment Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 36 Gy / 9 fractions
Description: 36 Gy- 9 Treatments, 4 1/2 Treatment Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 36 Gy / 9 fractions
Description: 36 Gy- 9 Treatments, 4 1/2 Treatment Days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 36 Gy / 9 fractions
Description: 36 Gy- 9 Treatments, 4 1/2 Treatment Days
Study: NCT01044771

Intervention type: DRUG
Group type: OTHER
Intervention: change from tenofovir to raltegravir
Description: Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
Study: NCT04379024

Intervention type: DRUG
Group type: OTHER
Intervention: DUAVEE 0.45Mg-20Mg Tablet
Description: One capsule daily for 6 months (+/- 1 month)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUAVEE 0.45Mg-20Mg Tablet
Description: One capsule daily for 6 months (+/- 1 month)
Study: NCT00694577

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 40 Gy /10 fractions
Description: 40 Gy-10 Treatments, 5 Treatment days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 40 Gy /10 fractions
Description: 40 Gy-10 Treatments, 5 Treatment days
Study: NCT02154334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
Study: NCT00694577

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 40 Gy /10 fractions
Description: 40 Gy-10 Treatments, 5 Treatment days
Study: NCT01924039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Enhancement Therapy
Description: The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Motivational Enhancement Therapy
Description: The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.

Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: Treatment as usual includes case management as well as psychiatric appointments.
Study: NCT02952313

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Implant
Study: NCT01969968

Intervention type: OTHER
Group type: OTHER
Intervention: Lipophilic Organic Polluants dosage
Description: Urinary, blood and fat dosage of Lipophilic Organic Polluants

Intervention type: OTHER
Group type: OTHER
Intervention: Lipophilic Organic Polluants dosage
Description: Urinary, blood and fat dosage of Lipophilic Organic Polluants

Intervention type: OTHER
Group type: OTHER
Intervention: Lipophilic Organic Polluants dosage
Description: Urinary, blood and fat dosage of Lipophilic Organic Polluants
Study: NCT02069821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination administration
Description: combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination administration
Description: combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
Study: NCT00705445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplementation without Zinc
Description: This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplementation with Zinc
Description: This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counselling and Education
Description: This will contain Nutritional Counselling and Education.
Study: NCT01271907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 25 mg/m\^2 x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 25 mg/m\^2 x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 25 mg/m\^2 x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
Description: Up to 1x10e10 CTL-05 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
Description: Up to 1x10e10 CTL-05 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
Description: Up to 1x10e10 CTL-05 cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection